
ResMed Inc. (RMD)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more- Previous Close
213.81 - Open
206.00 - Bid --
- Ask --
- Day's Range
198.64 - 206.84 - 52 Week Range
198.64 - 293.81 - Volume
2,826,146 - Avg. Volume
1,135,311 - Market Cap (intraday)
29.867B - Beta (5Y Monthly) 0.93
- PE Ratio (TTM)
19.77 - EPS (TTM)
10.37 - Earnings Date Apr 30, 2026
- Forward Dividend & Yield 2.40 (1.17%)
- Ex-Dividend Date May 14, 2026
- 1y Target Est
273.40
Recent News: RMD
View MorePerformance Overview: RMD
Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Earnings Trends: RMD
View MoreAnalyst Insights: RMD
View MoreStatistics: RMD
View MoreValuation Measures
-
Market Cap
29.87B
-
Enterprise Value
29.05B
-
Trailing P/E
19.77
-
Forward P/E
17.36
-
PEG Ratio (5yr expected)
1.26
-
Price/Sales (ttm)
5.43
-
Price/Book (mrq)
4.60
-
Enterprise Value/Revenue
5.25
-
Enterprise Value/EBITDA
13.33
Financial Highlights
Profitability and Income Statement
-
Profit Margin
27.44%
-
Return on Assets (ttm)
14.71%
-
Return on Equity (ttm)
25.25%
-
Revenue (ttm)
5.54B
-
Net Income Avi to Common (ttm)
1.52B
-
Diluted EPS (ttm)
10.37
Balance Sheet and Cash Flow
-
Total Cash (mrq)
1.66B
-
Total Debt/Equity (mrq)
12.99%
-
Levered Free Cash Flow (ttm)
1.45B
Compare To: RMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: RMD
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: RMD
View More-
ResMed Earnings: Slight Slowdown in US Devices, but Mask Sales Strong and Profitability Improving
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
RatingPrice Target -
Lowering target price to $239.00
RESMED INC has an Investment Rating of BUY; a target price of $239.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target -
Lowering target price to $243.00
RESMED INC has an Investment Rating of BUY; a target price of $243.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target -
Raising target price to $254.00
RESMED INC has an Investment Rating of BUY; a target price of $254.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target








